Fluoroquinolones in the management of community-acquired pneumonia in primary care

References

• Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis.44(Suppl. 2), S27–S72 (2007).
   PubMed Web of Science ®Google Scholar
• Niederman MS, Mandell LA, Anzueto A et al. American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Am. J. Respir. Crit. Care. Med.163, 1730–1754 (2001).
   PubMed Web of Science ®Google Scholar
• Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian R. The cost of treating community-acquired pneumonia. Clin. Ther.20, 820–837 (1998).
   PubMed Web of Science ®Google Scholar
• DeFrances CJ, Podgornik MN. 2004 national hospital discharge survey. Adv. Data371, 1–20 (2006).
   PubMedGoogle Scholar
• Escobar GJ, Fireman BH, Palen TE et al. Risk adjusting community-acquired pneumonia hospital outcomes using automated databases. Am. J. Manag. Care14, 158–166 (2008).
   PubMedGoogle Scholar
• Woodhead M, Welch CA, Harrison DA, Bellingan G, Ayres JG. Community-acquired pneumonia on the intensive care unit: secondary analysis of 17,869 cases in the ICNARC CASE Mix Programme Database. Crit. Care10(Suppl. 2), S1 (2006).
   PubMed Web of Science ®Google Scholar
• Stanton MW. Improving Treatment Decisions for Patients with Community-Acquired Pneumonia. Agency for Healthcare Research and Quality, Rockville, MD, USA (2002).
   Google Scholar
• Colice GL, Morley MA, Asche C, Birnbaum HG. Treatment costs of community-acquired pneumonia in an employed population. Chest125, 2140–2145 (2004).
   PubMed Web of Science ®Google Scholar
• Lave JR, Lin JL, Fine MJ, Hughes-Cromwick P. The cost of treating patients with community-acquired pneumonia. Semin. Respir. Crit. Care Med.20, 189–197 (1999).
   Web of Science ®Google Scholar
• Waterer GW, Buckingham SC, Kessler LA, Quasney MW, Wunderink RG. Decreasing β-lactam resistance in pneumococci from the Memphis region: analysis of 2,152 isolates from 1996 to 2001. Chest124, 519–525 (2003).
   PubMed Web of Science ®Google Scholar
• Whitley CG, Farley MM, Hadler J et al.; for the Active Bacterial Core Surveillance of the Emerging Infections Program Network. Decline in invasive pneumococcal disease after the introduction of protein–polysaccharide conjugate vaccine. N. Engl. J. Med.348, 1737 (2003).
   PubMedGoogle Scholar
• Mera R, Miller LA, Fritsche TR, Jones RN. Serotype replacement and multiple resistance in Streptococcus pneumoniae after the introduction of the conjugate pneumococcal vaccine. Microb. Drug Resist.14, 101–107 (2008).
   PubMed Web of Science ®Google Scholar
• Feldman C. Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia. J. Lab. Clin. Med.143, 269–283 (2004).
   PubMedGoogle Scholar
• Metlay JP, Singer DE. Outcomes in lower respiratory tract infections and the impact of antimicrobial drug resistance. Clin. Microbiol. Infect.8(Suppl. 2), 1–11 (2002).
   PubMed Web of Science ®Google Scholar
• Mandell LA, Bartlett JG, Dowell SF, File TM Jr, Musher DM, Whitney C. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin. Infect. Dis.37, 1405–1433 (2003).
   PubMed Web of Science ®Google Scholar
• Kollef MH. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin. Infect. Dis.31(Suppl. 4), S131–S138 (2000).
   Google Scholar
• Roson B, Carratala J, Fernandez-Sabe N et al. Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. Arch. Intern. Med.164, 502–508 (2004).
   PubMedGoogle Scholar
• Arancibia F, Ewig S, Martinez JA et al. Antimicrobial treatment failure in patients with community-acquired pneumonia. Am. J. Respir. Crit. Care Med.162, 154–160 (2000).
   PubMed Web of Science ®Google Scholar
• Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia. Clin. Infect. Dis.31, 347–382 (2000).
   PubMed Web of Science ®Google Scholar
• Eiland EH, Wargo KA, Hamm W, Hassoun AAM. Analysis of adherence to national nosocomial pneumonia treatment guidelines. Ther. Clin. Risk Manag.3, 983–988 (2007).
   PubMedGoogle Scholar
• Jackson ML, Neuzil KM, Thompson WW et al. The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin. Infect. Dis.39, 1642–1650 (2004).
   PubMed Web of Science ®Google Scholar
• Anzueto A, Niederman MS, Pearle J, Restrepo MI, Heyder A, Choudhri SH. Community-acquired pneumonia recovery in the elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy. Clin. Infect. Dis.42, 73–81 (2006).
   PubMed Web of Science ®Google Scholar
• De Roux A, Marcos MA, Garcia E et al. Viral community-acquired pneumonia in nonimmunocomprosmied adults. Chest125, 1343–1351 (2004).
   PubMed Web of Science ®Google Scholar
• Templeton KE, Scheltina SA, van den Eeden WC, Graffelman AW, van den Broek PJ, Claas ECJ. Improved diagnosis of the etiology of community-acquired pneumonia with real-time polymerase chain reaction. Clin. Infect. Dis.41, 345–351 (2005).
   PubMed Web of Science ®Google Scholar
• Benninger M, Segreti J. Is it bacterial or viral? Criteria for distinguishing bacterial and viral infections. J. Fam. Pract.57, S5–S11 (2008).
   Google Scholar
• Ruiz-Gonzalez A, Falguera M, Nogues A, Rubio-Caballero M. Is Streptococcus pneumoniae the leading cause of pneumonia of unknown etiology? A microbiologic study of lung aspirates in consecutive patients with community-acquired pneumonia. Am. J. Med.106, 385–390 (1999).
   PubMed Web of Science ®Google Scholar
• Gotfried MH. Epidemiology of clinically diagnosed community-acquired pneumonia in the primary care setting: results from the 1999–2000 Respiratory Surveillance Program. Am. J. Med.111(9 Suppl. 1), 25–29 (2001).
   Google Scholar
• Marrie TJ, Poulin-Costello M, Beecroft MD, Herman-Gnjidic Z. Etiology of community-acquired pneumonia treated in an ambulatory setting. Respir. Med.99(1), 60–65 (2005).
   PubMedGoogle Scholar
• Wattanathum A, Chaoprasong C, Nunthapisud P et al. Community-acquired pneumonia in southeast Asia: the microbial differences between ambulatory and hospitalized patients. Chest123(5), 1512–1519 (2003).
   PubMedGoogle Scholar
• Donowitz GR, Cox HL. Bacterial community-acquired pneumonia in older patients. Clin. Geriatr. Med.23(3), 515–534 (2007).
   PubMedGoogle Scholar
• File TM. Community-acquired pneumonia. Lancet362, 1991–2001 (2003).
   PubMed Web of Science ®Google Scholar
• Lieberman D, Schlaeffer F, Boldur I et al. Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients. Thorax51, 179–184 (1996).
   PubMed Web of Science ®Google Scholar
• Niederman MS, Feldman C, Richards GA. Combining information from prognostic scoring tools for CAP: an American view on how to get the best of all worlds. Eur. Respir. J.27, 9–11 (2006).
   PubMedGoogle Scholar
• Lim WS, van der Eerden MM, Laing R et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax58, 377–382 (2003).
   PubMed Web of Science ®Google Scholar
• Fine MJ, Auble TE, Yealy DM et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N. Engl. J. Med.336, 243–250 (1997).
   PubMed Web of Science ®Google Scholar
• Bodi M, Rodriguez A, Sole-Violan J et al. Antibiotic prescription for community-acquired pneumonia in the intensive care unit: impact of adherence to Infectious Diseases Society of America guidelines on survival. Clin. Infect. Dis.41, 1709–1716 (2005).
   PubMed Web of Science ®Google Scholar
• Houck PM, Bratzler DW, Nsa W, Ma A, Bartlett JG. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch. Intern. Med.164, 637–644 (2004).
   PubMedGoogle Scholar
• Baum SG, Kaltsas A. Guideline tyranny: primum no nocere. Clin. Infect. Dis.46, 1879–1880 (2008).
   PubMedGoogle Scholar
• Linder JA, Huang ES, Steinman MA, Gonzales R, Stafford RS. Fluoroquinolone prescribing in the United States: 1995 to 2002. Am. J. Med.118, 259–268 (2005).
   PubMed Web of Science ®Google Scholar
• Carrie AG, Kozyrskyyj AL. Outpatient treatment of community-acquired pneumonia: evolving trends and a focus on fluoroquinolones. Can. J. Clin. Pharmacol.13, e102–e111 (2006).
   PubMedGoogle Scholar
• Avelox (moxifloxacin hydrochloride). United States prescribing information. Bayer Pharmaceuticals Corporation, Wayne, NJ, USA (2010).
   Google Scholar
• Levaquin (levofloxacin). United States prescribing information. Ortho-McNeil, Raritan, NJ, USA (2009).
   Google Scholar
• Factive (gemifloxacin mesylate). United States prescribing information. Oscient Pharmaceuticals Corporation, Waltham, NJ, USA (2008).
   Google Scholar
• Segreti J, House HR, Siegel RE. Principles of antibiotic treatment of community-acquired pneumonia in the outpatient setting. Am. J. Med.118(7 Suppl. 1), 21–28 (2005).
   Google Scholar
• Bhavnani SM, Andes DR. Gemifloxacin for the treatment of respiratory tract infections: in vitro susceptibility, pharmacokinetics and pharmacodynamics, clinical efficacy, and safety. Pharmacotherapy25, 717–740 (2005).
   PubMed Web of Science ®Google Scholar
• Lister PD, Sanders CC. Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin. J. Antimicrob. Chemother.47, 811–818 (2001).
   PubMedGoogle Scholar
• Wispelwey B. Clinical implications of pharmacokinetics and pharmacodynamics of fluoroquinolones. Clin. Infect. Dis.41(Suppl. 2), S127–S135 (2005).
   PubMed Web of Science ®Google Scholar
• Scheld WM. Maintaining fluoroquinolone class efficacy: review of influencing factors. Emerg. Infect. Dis.9(1), 1–9 (2003).
   PubMed Web of Science ®Google Scholar
• Oldenholt I, Cars O. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae, and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model. J. Antimicrob. Chemother.58, 960–965 (2006).
   PubMedGoogle Scholar
• Oncu S. Treatment of community-acquired pneumonia, with special emphasis on gemifloxacin. Ther. Clin. Risk Manag.3, 441–448 (2007).
   PubMedGoogle Scholar
• Capitano B, Mattoes HM, Shore E et al. Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. Chest125, 965–973 (2004).
   PubMed Web of Science ®Google Scholar
• Rodvold K, Neuhauser M. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Pharmacotherapy21, 233s–252s (2001).
   PubMed Web of Science ®Google Scholar
• Breilh D, Jougon J, Djabarouti S et al. Diffusion of oral and intravenous 400 mg once-daily moxifloxacin into lung tissue at pharmacokinetic steady-state. J. Chemother.15, 558–562 (2003).
   PubMed Web of Science ®Google Scholar
• Noreddin AM, Reese AA, Ostroski M, Hoban DJ, Zhanel GG. Comparative pharmacodynamics of garenoxacin, gemifloxacin, and moxifloxacin in community-acquired pneumonia caused by Streptococcus pneumoniae: a Monte Carlo simulation analysis. Clin. Ther.29, 2685–2689 (2007).
   PubMed Web of Science ®Google Scholar
• Fogarty CM, Greenberg RN, Dunbar L et al. Effectiveness of levofloxacin for adult community-acquired pneumonia caused by macrolide-resistant Streptococcus pneumoniae: integrated results from four open-label, multicenter, Phase III clinical trials. Clin. Ther.23, 425–439 (2001).
   PubMed Web of Science ®Google Scholar
• Lode H, File TM Jr, Mandell L, Ball P, Pypstra R, Thomas M. 185 Gemifloxacin Study Group. Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability. Clin. Ther.24, 1915–1936 (2002).
   PubMed Web of Science ®Google Scholar
• Welte T, Petermann Q, Shurmann D, Bauer TT, Reimnitz P; MOXIRAPID Study Group. Treatment with sequential intravenousor oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy. Clin. Infect. Dis.41, 1697–1705 (2005).
   PubMed Web of Science ®Google Scholar
• Finch R, Schurmann D, Collins O et al. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob. Agents Chemother.46, 1746–1754 (2002).
   PubMed Web of Science ®Google Scholar
• Doern GV. Antimicrobial resistance with Streptococcus pneumoniae: much ado about nothing? Semin. Respir. Infect.16, 177–185 (2001).
   PubMedGoogle Scholar
• Doern GV, Richter SS, Miller A et al. Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes? Clin. Infect. Dis.41, 139–148 (2005).
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Roberts D, Waltky A et al. Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae. J. Antimicrob. Chemother.49, 807–812 (2002).
   PubMed Web of Science ®Google Scholar
• Bhavnani SM, Hammel JP, Jones RN, Ambrose PG. Relationship between increased levofloxacin use and decreased susceptibility of Streptococcus pneumoniae in the United States. Diagn. Microbiol. Infect. Dis.51, 31–37 (2005).
   PubMed Web of Science ®Google Scholar
• Ryan RJ, Lindsell C, Sheehan P. Fluoroquinolone resistance during 2000–2005: an observational study. BMC Infect. Dis.8, 71 (2008).
   PubMed Web of Science ®Google Scholar
• Schafer J, Hovde LB, Simonson D, Rotschafer JC. In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutant. Diagn. Microbiol. Infect. Dis.60, 155–161 (2008).
   PubMed Web of Science ®Google Scholar
• Iannini PB. The safety profile of moxifloxacin and other fluoroquinolones in special patient populations. Curr. Med. Res. Opin.23, 1403–1413 (2007).
   PubMed Web of Science ®Google Scholar
• Shorr AF, Zadeikis N, Xiang JX, Tennenberg AM, Wes Ely E. A multicenter, randomized, double-blind, retrospective comparison of 5- and 10-day regimens of levofloxacin in a subgroup of patients aged > or =65 years with community-acquired pneumonia. Clin. Ther.27, 1251–1259 (2005).
   PubMed Web of Science ®Google Scholar
• Leroy O, Saux P, Bédos JP, Caulin E. Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors. Chest128, 172–183 (2005).
   PubMed Web of Science ®Google Scholar
• Morganroth J, DiMarco JP, Anzueto A, Niederman MS, Choudhri S; CAPRIE Study Group. A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia. Chest128, 3398–3406 (2005).
   PubMed Web of Science ®Google Scholar
• Torres A, Garau J, Arvis P et al. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study – a randomized clinical trial. Clin. Infect. Dis.46, 1499–1509 (2008).
   PubMed Web of Science ®Google Scholar
• Ball P, File TM, Twynholm M, Henkel T; 061 study group. Efficacy and safety of gemifloxacin 320 mg once-daily for 7 days in the treatment of adult lower respiratory tract infections. Int. J. Antimicrob. Agents18, 19–27 (2001).
   PubMed Web of Science ®Google Scholar
• File TM Jr, Schlemmer B, Garau J, Cupo M, Young C; 049 Clinical Study Group. Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin. J. Antimicrob. Chemother.48, 67–74 (2001).
   PubMed Web of Science ®Google Scholar
• Leophonte P, File T, Feldman C. Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin. Respir. Med.98, 708–720 (2004).
   PubMed Web of Science ®Google Scholar
• File TM Jr, Mandell LA, Tillotson G, Kostov K, Georgiev O. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study. J. Antimicrob. Chemother.60, 112–120 (2007).
   PubMed Web of Science ®Google Scholar
• Dunbar LM, Wunderink RG, Habib MP et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin. Infect. Dis.37, 752–760 (2003).
   PubMed Web of Science ®Google Scholar
• Carratala J, Fernandez-Sabe N, Ortega L et al. Outpatient care compared with hospitalization for community-acquired pneumonia. Ann. Intern. Med.142, 165–172 (2005).
   PubMed Web of Science ®Google Scholar
• Rittenhouse BE, Stinnett AA, Dulisse B et al. An economic evaluation of levofloxacin versus cefuroxime axetil in the outpatient treatment of adults with community-acquired pneumonia. Am. J. Manag. Care6, 381–389 (2000).
   PubMedGoogle Scholar
• Ye X, Sikirica V, Schein JR et al. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis. Clin. Ther.30, 358–371 (2008).
   PubMed Web of Science ®Google Scholar
• Torres A, Muir JF, Corris P et al. Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia. Eur. Respir. J.21, 135–143 (2003).
   PubMed Web of Science ®Google Scholar
• Faich GA, Morganroth J, Whitehouse AB et al. Clinical experience with moxifloxacin in patients with respiratory tract infections. Ann. Pharmacother.38, 749–754 (2004).
   PubMed Web of Science ®Google Scholar
• Fogarty C, Torres A, Choudhri S, Haverstock D, Herrington J, Ambler J. Efficacy of moxifloxacin for treatment of penicillin-, macrolide- and multidrug-resistance Streptococcus pneumoniae in community-acquired pneumonia. Int. J. Clin. Pract.59, 1253–1259 (2005).
   PubMedGoogle Scholar
• Martin M, Quilici S, File T, Garau J, Kureishi A, Kubin M. Cost–effectiveness of empirical prescribing of antimicrobials in community-acquired pneumonia in three countries in the presence of resistance. J. Antimicrob. Chemother.59, 977–989 (2007).
   PubMed Web of Science ®Google Scholar
• Martin M, Moore L, Quilici S, Decramer M, Simoens S. A cost–effectiveness analysis of antimicrobial treatment of community-acquired pneumonia taking into account resistance in Belgium. Curr. Med. Res. Opin.24, 737–751 (2008).
   PubMed Web of Science ®Google Scholar